JP2020527583A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527583A5 JP2020527583A5 JP2020502652A JP2020502652A JP2020527583A5 JP 2020527583 A5 JP2020527583 A5 JP 2020527583A5 JP 2020502652 A JP2020502652 A JP 2020502652A JP 2020502652 A JP2020502652 A JP 2020502652A JP 2020527583 A5 JP2020527583 A5 JP 2020527583A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- treatment
- enantiomer
- bhb
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 15
- 230000004770 neurodegeneration Effects 0.000 claims 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 208000010877 cognitive disease Diseases 0.000 claims 7
- 235000015872 dietary supplement Nutrition 0.000 claims 6
- 208000024827 Alzheimer disease Diseases 0.000 claims 5
- HIWZHLUXGVVBPK-UHFFFAOYSA-N butane-1,3-diol;3-hydroxybutanoic acid Chemical compound CC(O)CCO.CC(O)CC(O)=O HIWZHLUXGVVBPK-UHFFFAOYSA-N 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
- 206010049565 Muscle fatigue Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 235000020887 ketogenic diet Nutrition 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 230000009467 reduction Effects 0.000 claims 4
- 230000004580 weight loss Effects 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 150000001720 carbohydrates Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 208000021642 Muscular disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 2
- 206010002022 amyloidosis Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 235000021588 free fatty acids Nutrition 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 230000037219 healthy weight Effects 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000011661 metabolic syndrome X Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- 230000001988 toxicity Effects 0.000 claims 2
- 231100000419 toxicity Toxicity 0.000 claims 2
- 230000004584 weight gain Effects 0.000 claims 2
- 235000019786 weight gain Nutrition 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000007107 neurocognitive deficit Effects 0.000 claims 1
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535754P | 2017-07-21 | 2017-07-21 | |
| US62/535,754 | 2017-07-21 | ||
| PCT/US2018/042948 WO2019018683A1 (en) | 2017-07-21 | 2018-07-19 | BETA-HYDROXYBUTYRATE AND BUTANEDIOL ENANTIOMERS AND METHODS OF USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527583A JP2020527583A (ja) | 2020-09-10 |
| JP2020527583A5 true JP2020527583A5 (enExample) | 2021-09-09 |
| JP7442095B2 JP7442095B2 (ja) | 2024-03-04 |
Family
ID=65015819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502652A Active JP7442095B2 (ja) | 2017-07-21 | 2018-07-19 | ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11773051B2 (enExample) |
| EP (1) | EP3654963A4 (enExample) |
| JP (1) | JP7442095B2 (enExample) |
| KR (1) | KR102795284B1 (enExample) |
| CN (1) | CN111050764A (enExample) |
| AU (1) | AU2018304380B2 (enExample) |
| BR (1) | BR112020001285A2 (enExample) |
| CA (1) | CA3070453A1 (enExample) |
| IL (1) | IL272173B2 (enExample) |
| MX (1) | MX2020000734A (enExample) |
| WO (1) | WO2019018683A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10245243B1 (en) * | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US12533346B2 (en) | 2016-04-19 | 2026-01-27 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
| US12109182B2 (en) | 2016-04-19 | 2024-10-08 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US20230346721A1 (en) | 2018-04-18 | 2023-11-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies |
| US12329734B2 (en) | 2017-12-19 | 2025-06-17 | Axcess Global Sciences, Llc | Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US12496283B2 (en) | 2016-04-19 | 2025-12-16 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate and related compounds in humans |
| US12521378B2 (en) | 2016-04-19 | 2026-01-13 | Axcess Global Sciences, Llc | Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans |
| WO2017213999A1 (en) | 2016-06-07 | 2017-12-14 | The J. David Gladstone Institutes | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
| IL272173B2 (en) | 2017-07-21 | 2025-06-01 | Buck Inst Res Aging | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same |
| US12090129B2 (en) | 2017-11-22 | 2024-09-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| WO2019147503A1 (en) | 2018-01-25 | 2019-08-01 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| WO2020167692A1 (en) * | 2019-02-11 | 2020-08-20 | Access Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the r-enantiomer and methods of use |
| WO2020167693A1 (en) * | 2019-02-11 | 2020-08-20 | Access Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with s-enantiomer |
| JP7448555B2 (ja) * | 2019-02-11 | 2024-03-12 | アクセス・グローバル・サイエンシーズ・エルエルシー | ラセミベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法 |
| CN109806251A (zh) * | 2019-03-04 | 2019-05-28 | 清华大学 | 3-羟基丁酸及其衍生物在制备抗动脉粥样硬化的产品中的应用 |
| EP3937920B1 (en) | 2019-03-14 | 2025-07-09 | The Regents of the University of California | Compositions comprising beta-hydroxybutyrate and citrate for supporting renal health |
| US12472200B2 (en) | 2019-05-15 | 2025-11-18 | Axcess Global Sciences, Llc | Autobiotic compositions and method for promoting healthy gut microbiome |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US12167993B2 (en) | 2019-06-21 | 2024-12-17 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| EP4146337B1 (de) * | 2020-07-13 | 2024-04-17 | KetoLipix Therapeutics GmbH | Verfahren zur herstellung von polyglycerinestern von mit oxobutanol veresterten polycarbonsäuren |
| WO2022012766A1 (de) * | 2020-07-13 | 2022-01-20 | Ioi Oleo Gmbh | Verfahren zur herstellung von oxobutanol-estern von polymeren carbonsäuren |
| US12186297B2 (en) | 2020-08-26 | 2025-01-07 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
| CN112341542B (zh) * | 2021-01-08 | 2021-05-14 | 清华大学 | 一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用 |
| US20220249497A1 (en) * | 2021-02-05 | 2022-08-11 | Health Via Modern Nutrition, Inc. | Compositions and methods for improving relaxation, sleep, cognition, and/or physical performance |
| WO2023283654A1 (en) * | 2021-07-09 | 2023-01-12 | Georgia State University Research Foundation, Inc. | The use of beta-hydroxybutyrates for the treatment or prevention of aneurysms and dissections |
| WO2023212091A1 (en) * | 2022-04-29 | 2023-11-02 | Buck Institute For Research On Aging | Novel ketone ester compounds |
| EP4566598A1 (en) * | 2023-12-04 | 2025-06-11 | ZoSaLa Pharma, Inc | Compositions providing sglt2i and bhb activity and methods of use to treat human disease |
| WO2025166164A1 (en) | 2024-02-02 | 2025-08-07 | Selah Therapeutics Limited | DL- AND L-β-HYDROXYBUTYRATE AND METHODS OF USE THEREOF |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS42663Y1 (enExample) | 1966-03-07 | 1967-01-17 | ||
| US4263216A (en) | 1978-10-20 | 1981-04-21 | The Procter & Gamble Company | Diglyceride manufacture |
| US4436726A (en) | 1980-12-15 | 1984-03-13 | Fujisawa Pharmaceutical Co., Ltd. | N-Acylpeptide compound, processes for the preparation thereof and the pharmaceutical compositions |
| BE1001209A3 (fr) * | 1987-11-19 | 1989-08-22 | Solvay | Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol. |
| US5126373A (en) * | 1987-11-19 | 1992-06-30 | Henri Brunengraber | Composition for parenteral and oral nutrition |
| DE68928956T2 (de) | 1988-04-27 | 1999-07-29 | Daicel Chemical Industries, Ltd., Sakai, Osaka | Verfahren zur Herstellung von optisch aktivem 1,3-Butanediol |
| JP2578658B2 (ja) | 1989-02-21 | 1997-02-05 | チッソ株式会社 | 光学活性化合物及びその製造法 |
| US5008126A (en) | 1989-06-27 | 1991-04-16 | Nabisco Brands, Inc. | Long chain diol diesters as low calorie fat mimetics |
| IT1240760B (it) | 1990-02-12 | 1993-12-17 | Sigma Tau Ind Farmaceuti | Esteri di acil-l-carnitine con l'acido gamma-idrossibutirrico e composizioni farmaceutiche che li contengono per l'inibizione della degenerazione neuronale e nel trattamento del coma. |
| ES2079083T3 (es) | 1992-01-08 | 1996-01-01 | Nestle Sa | Composicion cosmetica o dermatologica que contiene un diol diester. |
| DE19703471A1 (de) | 1997-01-31 | 1998-08-06 | Beiersdorf Ag | Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Butylenglycoldiestern |
| AU6513298A (en) | 1997-03-17 | 1998-10-12 | British Technology Group Limited | Therapeutic compositions |
| WO1998051278A2 (en) | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| EP1052240B1 (en) | 1999-05-11 | 2003-03-19 | Dow AgroSciences LLC | Process for the preparation of substituted 3-hydroxybutyrate esters |
| US20080009467A1 (en) | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
| EP1363879A2 (en) | 2000-10-11 | 2003-11-26 | Esperion Therapeutics Inc. | Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| AU2004204778B2 (en) | 2003-01-10 | 2008-05-22 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with 2-deoxyglucose |
| AU2004245567B2 (en) | 2003-06-03 | 2011-06-23 | Oxford University Innovation Limited | Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives |
| EP1528053A1 (en) | 2003-10-31 | 2005-05-04 | Lonza Ag | Process for the preparation of (S)- or (R)-4-halo-3-hydroxybutyrates |
| JP2006063001A (ja) | 2004-08-25 | 2006-03-09 | Takasago Internatl Corp | 光学活性β−ブチロラクトンの製造方法 |
| US20070203276A1 (en) | 2006-02-10 | 2007-08-30 | Gyorgyi Fenyvesi | Plasticizers comprising biologically-based mono and di esters |
| JP5054418B2 (ja) | 2007-04-23 | 2012-10-24 | ポーラ化成工業株式会社 | クレンジング用の化粧料に好適な皮膚外用剤 |
| US8642654B2 (en) | 2009-04-16 | 2014-02-04 | Isis Innovation Limited | Hydroxybutyrate ester and medical use thereof |
| ES2655367T3 (es) * | 2008-08-21 | 2018-02-19 | Oxford University Innovation Limited | Bebida que comprende éster de hidroxibutirato y uso médico de la misma |
| US9034613B2 (en) * | 2009-04-16 | 2015-05-19 | Isis Innovation Limited | Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing Lactobacillus brevis alcohol dehydrogenase |
| GB201002983D0 (en) | 2010-02-22 | 2010-04-07 | Tdeltas Ltd | Nutritinal composition |
| CA2797679A1 (en) | 2010-04-28 | 2011-11-03 | Arkema Inc. | Method of improving stability of polyurethane polyol blends containing halogenated olefin blowing agent |
| KR101243240B1 (ko) | 2010-07-19 | 2013-04-04 | (주)에이씨티 | 신규 알킬디올 유도체화합물 및 이를 포함하는 미백용 피부외용제조성물 |
| CN103360243B (zh) | 2012-03-31 | 2015-06-17 | 中国石油化工股份有限公司 | 一种1,3-二酰氧基丙烷类化合物的制备方法 |
| JP5146628B1 (ja) | 2012-05-01 | 2013-02-20 | コニカミノルタアドバンストレイヤー株式会社 | 位相差フィルム、偏光板の製造方法および液晶表示装置 |
| EP2925308B1 (en) | 2012-11-28 | 2019-12-25 | University Of South Florida | Targeting cancer with metabolic therapy and hyperbaric oxygen |
| CN105246870A (zh) | 2013-03-14 | 2016-01-13 | 伊希斯创新有限公司 | (r)-3-羟基丁酸(r)-3-羟基丁酯的制备方法 |
| PE20151949A1 (es) | 2013-03-19 | 2016-01-05 | Univ South Florida | Composiciones y metodos para producir cetosis elevada y sostenida |
| US11814664B2 (en) | 2013-05-24 | 2023-11-14 | Genomatica, Inc. | Microorganisms and methods for producing (3R)-hydroxybutyl (3R)-hydroxybutyrate |
| EP3030323B1 (en) | 2013-08-06 | 2019-04-24 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
| WO2016123229A1 (en) * | 2015-01-29 | 2016-08-04 | Yale University | Compositions and methods for treating nlrp3 inflammasome-related diseases and disorders |
| EP3322427A4 (en) * | 2015-07-10 | 2019-07-17 | Cognate Nutritionals, Inc. | MIGRAINE PROPHYLAXIS AND MITIGATION USING MEDIUM CHAIN TRIGLYCERIDES, KETONE ESTERS, AND OTHER KETOGENIC SOURCES |
| US10245242B1 (en) | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| WO2017213999A1 (en) | 2016-06-07 | 2017-12-14 | The J. David Gladstone Institutes | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same |
| IL272173B2 (en) | 2017-07-21 | 2025-06-01 | Buck Inst Res Aging | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same |
| WO2019147503A1 (en) * | 2018-01-25 | 2019-08-01 | Buck Institute For Research On Aging | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds |
| US20190262415A1 (en) | 2018-02-26 | 2019-08-29 | Ketologie LLC | Supplement for inducing and sustaining nutritional ketosis |
| WO2021211609A1 (en) | 2020-04-16 | 2021-10-21 | Buck Institute For Research On Aging | Treatment of viral pathologies with exogenous ketones |
-
2018
- 2018-07-19 IL IL272173A patent/IL272173B2/en unknown
- 2018-07-19 KR KR1020207004340A patent/KR102795284B1/ko active Active
- 2018-07-19 MX MX2020000734A patent/MX2020000734A/es unknown
- 2018-07-19 JP JP2020502652A patent/JP7442095B2/ja active Active
- 2018-07-19 CN CN201880056204.3A patent/CN111050764A/zh active Pending
- 2018-07-19 US US16/631,374 patent/US11773051B2/en active Active
- 2018-07-19 AU AU2018304380A patent/AU2018304380B2/en active Active
- 2018-07-19 WO PCT/US2018/042948 patent/WO2019018683A1/en not_active Ceased
- 2018-07-19 CA CA3070453A patent/CA3070453A1/en active Pending
- 2018-07-19 BR BR112020001285-8A patent/BR112020001285A2/pt not_active Application Discontinuation
- 2018-07-19 EP EP18835222.3A patent/EP3654963A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527583A5 (enExample) | ||
| JP6446552B2 (ja) | 体重と体脂肪減少に用いられる組成物およびその医薬品と使用 | |
| JP2012500264A5 (enExample) | ||
| AU2016201325B2 (en) | Methods Of Providing Weight Loss Therapy In Patients With Major Depression | |
| WO2018052020A1 (ja) | 睡眠障害改善剤及び睡眠障害の改善方法 | |
| Chokroverty | Differential diagnoses of restless legs syndrome/Willis-Ekbom disease: mimics and comorbidities | |
| JP6669665B2 (ja) | 体重管理にシンナムアルデヒド及び亜鉛を用いるための方法及び組成物 | |
| US20210353671A1 (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
| Inoue et al. | Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndrome | |
| JP6947495B2 (ja) | Ｇａｂａを有効成分とする活気および／または活力向上剤 | |
| JP2016050198A (ja) | 睡眠障害改善剤 | |
| CN115279197A (zh) | 增强型含咖啡因饮料组合物 | |
| JP2016525134A (ja) | チグリンアルデヒドを使用する組成物及び方法 | |
| JP6368368B2 (ja) | ｐ−アニスアルデヒドを使用する組成物及び方法 | |
| CA3076180C (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| JP2016525133A (ja) | クミンアルデヒドを使用する組成物及び方法 | |
| Aboddy et al. | Drugs used for weight reduction among Iraqi population sample, a comparative study | |
| CN112641765B (zh) | 丙泊酚的抗疲劳制药用途 | |
| Sabaghi et al. | Ef-fects of Metformin on Weight Loss and Metabolic Control in Obese Patients With Schizophrenia and Schizoaffective Disor-der: A Randomized Double-Blind Controlled Clinical Trial | |
| Patel et al. | AYURVEDIC MANAGEMENT OF STHAULYA (CHILDHOOD OBESITY): A CASE STUDY | |
| Patil et al. | transient lingual papillitis: An unusual clinical presentation | |
| JPWO2021185890A5 (enExample) | ||
| WO2025257292A1 (en) | Combinations of urolithins with agents for improving brain health and agents for improving immune health | |
| CN118354774A (zh) | 基于副黄嘌呤的咖啡因替代品组合物及其在咖啡因慢速代谢者中的使用方法 | |
| CN120676936A (zh) | 用多西环素单独或与左旋多巴组合治疗神经退行性病症 |